Latest Steatohepatitis Stories
NY Times Article Brings Attention to Dangerous Lifestyle Related Epidemic and Suggests Critical Need for Therapy DENVER, July 1, 2014 /PRNewswire/ -- A recent New York Times article
SOUTH SAN FRANCISCO, June 30, 2014 /PRNewswire/ -- Tobira Therapeutics Inc., a clinical-stage biopharmaceutical company advancing cenicriviroc (CVC) in liver disease and HIV, announced today
Company Presents Positive Preclinical Efficacy Results at ICE/ENDO 2014 Meeting RALEIGH, N.C., June 23, 2014 /PRNewswire/ --
RALEIGH, N.C., June 18, 2014 /PRNewswire/ -- Islet Sciences, Inc. (OTCQB: ISLT), a biopharmaceutical company developing
DUBLIN and SAN DIEGO, May 12, 2014 /PRNewswire/ -- - Acquisition of Lumena Pharmaceuticals, a biopharmaceutical company with late stage rare disease
ReportsnReports.com offers "OpportunityAnalyzer: Nonalcoholic Steatohepatitis (NASH) - Opportunity Analysis and Forecasts to 2017 - Event-Driven Update" 2014 market research report in
Funding to support clinical development of treatments for rare cholestatic liver diseases and nonalcoholic steatohepatitis SAN DIEGO, March 11, 2014 /PRNewswire/ -- Lumena Pharmaceuticals
In-demand research report “OpportunityAnalyzer: Nonalcoholic Steatohepatitis (NASH) - Opportunity Analysis and Forecasts to 2017” elaborated by GlobalData has been recently published by Market
New research suggests that estrogen protects women with nonalcoholic steatohepatitis (NASH) from severe liver fibrosis.
- To swell, as grain or wood with water.